Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-341, D958
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT05921435
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT05897216
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-828, D064, D702
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 44
- Registration Number
- NCT05881707
- Locations
- 🇰🇷
Jeonbuk National University Hospital, Seoul, Korea, Republic of
Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults
Phase 1
Completed
- Conditions
- Type II Diabetes
- Interventions
- Drug: CKD-378 (low-dose)
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 23
- Registration Number
- NCT05881213
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
Phase 4
Not yet recruiting
- Conditions
- Essential HypertensionMetabolic Syndrome
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 116
- Registration Number
- NCT05843162
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-828, D064, D701
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 43
- Registration Number
- NCT05834595
- Locations
- 🇰🇷
Central hospital, Gyeonggi-do, Korea, Republic of
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05816759
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-348(5)Drug: CKD-828, D097, D337
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 65
- Registration Number
- NCT05749861
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378
Phase 1
Completed
- Conditions
- Type II Diabetes
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT05741437
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
Pharmacokinetics and Safety/Tolerability of CKD-379
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05719155
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath